Literature DB >> 11893032

Immunocytochemical expression of epidermal growth factor receptor in myoepithelial cells of the breast.

Donatella Santini1, Claudio Ceccarelli, Maria Lucia Tardio, Mario Taffurelli, Domenico Marrano.   

Abstract

The immunohistochemical expression and distribution of epidermal growth factor receptor (EGFr) in mammary myoepithelial cells (MECs) in normal tissue, benign epithelial proliferative lesions, and in situ carcinoma was performed. Results of the current study demonstrated that MECs stained constantly and strongly for EGFr, creating an outer continuous ring surrounding the epithelium of ducts and acini in healthy, in proliferative epithelial lesions, and in in situ carcinoma, both of ductal and lobular type. Foci of microinvasion were easily appreciated for the complete loss of EGFr immunostaining. Epidermal growth factor receptor expression in normal epithelia ranged from negative to weakly positive; it was positive in hyperplasia, whereas it was not constantly negative in in situ carcinoma. In conclusion, immunohistochemical staining for EGFr is diagnostically useful for MEC identification. The specific EGFr in MECs leads the authors to suggest that its expression may be related to the recently recognized high-specialized paracrine function by which the MECs exert the natural mechanical and functional role in the juxtaposition between epithelium and stoma.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11893032     DOI: 10.1097/00129039-200203000-00005

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  7 in total

1.  Prognostic Evaluation of Epidermal Growth Factor Receptor (EGFR) Genotype and Phenotype Parameters in Triple-negative Breast Cancers.

Authors:  Sofia Levva; Vassiliki Kotoula; Ioannis Kostopoulos; Kyriaki Manousou; Christos Papadimitriou; Kyriaki Papadopoulou; Sotiris Lakis; Kyriakos Koukoulias; Vasilios Karavasilis; George Pentheroudakis; Eufemia Balassi; Flora Zagouri; Ioannis G Kaklamanos; Dimitrios Pectasides; Evangelia Razis; Gerasimos Aravantinos; Pavlos Papakostas; Dimitrios Bafaloukos; Grigorios Rallis; Helen Gogas; George Fountzilas
Journal:  Cancer Genomics Proteomics       Date:  2017 May-Jun       Impact factor: 4.069

2.  The EGF signaling pathway influences cell migration and the secretion of metalloproteinases by myoepithelial cells in pleomorphic adenoma.

Authors:  Natalia Festugatto Navarini; Vera Cavalcanti de Araújo; Amy Louise Brown; Fabrício Passador-Santos; Isabela Fernandes de Souza; Marcelo Henrique Napimoga; Ney Soares Araújo; Elizabeth Ferreira Martinez
Journal:  Tumour Biol       Date:  2014-09-18

3.  Sustained activation of the HER1-ERK1/2-RSK signaling pathway controls myoepithelial cell fate in human mammary tissue.

Authors:  Lejla Pasic; T S Karin Eisinger-Mathason; Bisi T Velayudhan; Christopher A Moskaluk; David R Brenin; Ian G Macara; Deborah A Lannigan
Journal:  Genes Dev       Date:  2011-08-01       Impact factor: 11.361

4.  Myoepithelial carcinoma of the breast: a clinicopathological and immunohistochemical study of 15 diagnostically challenging cases.

Authors:  Natalia Buza; Nazila Zekry; Colette Charpin; Fattaneh A Tavassoli
Journal:  Virchows Arch       Date:  2010-07-24       Impact factor: 4.064

Review 5.  Genomic Changes in Normal Breast Tissue in Women at Normal Risk or at High Risk for Breast Cancer.

Authors:  David N Danforth
Journal:  Breast Cancer (Auckl)       Date:  2016-08-17

Review 6.  Do myoepithelial cells hold the key for breast tumor progression?

Authors:  Kornelia Polyak; Min Hu
Journal:  J Mammary Gland Biol Neoplasia       Date:  2005-07       Impact factor: 2.698

7.  Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis.

Authors:  Jorge S Reis-Filho; Fernanda Milanezi; Silvia Carvalho; Pete T Simpson; Dawn Steele; Kay Savage; Maryou B K Lambros; Emilio M Pereira; Jahn M Nesland; Sunil R Lakhani; Fernando C Schmitt
Journal:  Breast Cancer Res       Date:  2005-10-25       Impact factor: 6.466

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.